iBio

iBio Dividend

Dividend of iBio (IBIO) as of Nov 17, 2026.

Dividend

0.00USD

Last updated:

How much dividend does iBio 2026 pay?

According to the latest status from November 2026, iBio paid a total of 0.00 USD per share in dividends within the last 12 months. With the current iBio price of 0.71 USD, this corresponds to a dividend yield of - %. A dividend is paid times per year.

Historical iBio Dividends

Historical iBio Dividends
PaydateDividend

The iBio Dividend history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Date
Dividend
Jan 1, 2024
0.00 USD
Jan 1, 2025
0.00 USD
Jan 1, 2026
0.00 USD
Jan 1, 2027 (e)
0.00 USD
Jan 1, 2028 (e)
0.00 USD
Jan 1, 2029 (e)
0.00 USD
Jan 1, 2030 (e)
0.00 USD
Jan 1, 2031 (e)
0.00 USD
The iBio Dividend history
YEARDividendYoY
est0.00USD—
est0.00USD—
est0.00USD—
est0.00USD—
est0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—

Is the iBio Dividend Safe?

iBio has been increasing the dividend for 0 years.

Analysts expect a Dividend Cut of -100.00% for the current fiscal year.

Dividend Details

Understanding iBio's Dividend Distributions

iBio’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining iBio's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

iBio's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in iBio’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

iBio Stock analysis

What does iBio do? iBio, Inc. generates revenue through the commercialization of its plant-based protein expression technologies, which are used for developing vaccines and therapeutic proteins. The company's iBioLaunch technology and iBioModulator platform enable the production of biologics in hydroponically grown green plants, targeting fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant versions of plasma-derived products. Clients and collaborators purchase product development and manufacturing services, leveraging iBio's transformative platform for biologics production. The firm focuses on both its own product candidates and providing services to external partners in the biopharmaceutical sector. iBio's business model centers on offering its proprietary technologies as a service to clients, with a focus on developing and manufacturing biologics through plant-based systems. The company's technologies are applicable across multiple therapeutic areas, including fibrotic disease treatments, vaccine development, and enzyme replacement therapies. By providing these services, iBio supports clients in creating advanced biopharmaceutical products without the need for traditional manufacturing infrastructure. The company's revenue streams include the sale of its iBioLaunch and iBioModulator platforms, as well as product development and manufacturing services for biopharmaceutical clients. These services are tailored to meet the needs of partners seeking efficient, scalable production methods for biologics. iBio's focus on plant-based production differentiates it in the market, appealing to clients looking for innovative approaches to biologic manufacturing. iBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about iBio stock

iBio paid dividends every year for the past 0 years.

iBio is assigned to the 'Health' sector.

The dividends of iBio are distributed in USD.

Dividend calendar 2026

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

All Key Metrics — iBio